Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1985 Aug;85(4):849–859. doi: 10.1111/j.1476-5381.1985.tb11084.x

Platelet desensitization induced by arachidonic acid is not due to cyclo-oxygenase inactivation and involves the endoperoxide receptor.

L G Carmo, M Hatmi, D Rotilio, B B Vargaftig
PMCID: PMC1916664  PMID: 2994786

Abstract

Human platelets pre-exposed to arachidonic acid (AA) (0.1-1 mM) or to the endoperoxide analogue U46619 (1-3 microM) and then washed and resuspended, failed to respond with aggregation or secretion to a second challenge by either agonist. The response to thrombin at low (0.04-0.1 u ml-1) but not at high (2.5 u ml-1) concentrations was also inhibited by pre-exposure to AA and U46619. The ability of platelets to synthesize thromboxane (Tx) B2 from AA or upon challenge with thrombin persisted despite platelet desensitization. In the presence of the reversible cyclo-oxygenase (CO) inhibitors methyl salicylate (MS) or L8027, pre-exposure to AA had no effect on subsequent challenge by the same agonist or by U46619, whereas platelet desensitization by pre-exposure to U46619 persisted. However, platelet activation by, and desensitization to AA and U46619, was prevented by trimetoquinol and compound L636499, two thromboxane/endoperoxide receptor antagonists. In contrast to the CO inhibitors, the thromboxane synthetase inhibitor dazoxiben, which in 3 'responders' out of 5 subjects suppressed aggregation, secretion, and Tx formation induced by AA, failed to prevent AA-induced desensitization. Compared to quiescent cells the distances between platelets desensitized after re-exposure to AA were reduced in electron microscopy, but the tight connections associated with aggregated cells were not observed. Degranulation was also not observed and cell morphology resembled that of normal quiescent platelets. In conclusion, (a) AA and U46619 desensitize human platelets at a similar site sensitive to prostaglandin/thromboxane receptor antagonists, and show cross-desensitization; (b) desensitization by AA appears to be mediated by a CO-dependent metabolite, as CO inhibitors prevent desensitization by AA but not to U46619; (c) the failure of dazoxiben to prevent desensitization by AA suggests that a metabolite other than TxA2, possibly the endoperoxides, mediates the phenomenon; (d) desensitization does not involve inactivation of CO or thromboxane synthetase enzymes.

Full text

PDF
849

Images in this article

856Figure 6
on p.856

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aharony D., Smith J. B., Silver M. J. Regulation of arachidonate-induced platelet aggregation by the lipoxygenase product, 12-hydroperoxyeicosatetraenoic acid. Biochim Biophys Acta. 1982 Oct 8;718(2):193–200. doi: 10.1016/0304-4165(82)90219-7. [DOI] [PubMed] [Google Scholar]
  2. Armstrong R. A., Jones R. L., Wilson N. H. Ligand binding to thromboxane receptors on human platelets: correlation with biological activity. Br J Pharmacol. 1983 Aug;79(4):953–964. doi: 10.1111/j.1476-5381.1983.tb10541.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bartele V., Cerletti C., Schiepatti A., di Minno G., de Gaetano G. Inhibition of thromboxane synthetase does not necessarily prevent platelet aggregation. Lancet. 1981 May 9;1(8228):1057–1058. doi: 10.1016/s0140-6736(81)92224-8. [DOI] [PubMed] [Google Scholar]
  4. Bertelé V., Falanga A., Tomasiak M., Dejana E., Cerletti C., de Gaetano G. Platelet thromboxane synthetase inhibitors with low doses of aspirin: possible resolution of the "aspirin dilemma". Science. 1983 Apr 29;220(4596):517–519. doi: 10.1126/science.6682245. [DOI] [PubMed] [Google Scholar]
  5. Carrier R., Cragoe E. J., Ethier D., Ford-Hutchinson A. W., Girard Y., Hall R. A., Hamel P., Rokach J., Share N. N., Stone C. A. Studies on L-640,035: a novel antagonist of contractile prostanoids in the lung. Br J Pharmacol. 1984 Jun;82(2):389–395. doi: 10.1111/j.1476-5381.1984.tb10774.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Chan C. C., Nathaniel D. J., Yusko P. J., Hall R. A., Ford-Hutchinson A. W. Inhibition of prostanoid-mediated platelet aggregation in vivo and in vitro by 3-hydroxymethyl-dibenzo(b,f)thiepin 5,5-dioxide (L-640,035). J Pharmacol Exp Ther. 1984 Apr;229(1):276–282. [PubMed] [Google Scholar]
  7. Charo I. F., Feinman R. D., Detwiler T. C. Interrelations of platelet aggregation and secretion. J Clin Invest. 1977 Oct;60(4):866–873. doi: 10.1172/JCI108841. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Chignard M., Le Couedic J. P., Tence M., Vargaftig B. B., Benveniste J. The role of platelet-activating factor in platelet aggregation. Nature. 1979 Jun 28;279(5716):799–800. doi: 10.1038/279799a0. [DOI] [PubMed] [Google Scholar]
  9. Croset M., Lagarde M. Stereospecific inhibition of PGH2-induced platelet aggregation by lipoxygenase products of icosaenoic acids. Biochem Biophys Res Commun. 1983 May 16;112(3):878–883. doi: 10.1016/0006-291x(83)91699-6. [DOI] [PubMed] [Google Scholar]
  10. Egan R. W., Paxton J., Kuehl F. A., Jr Mechanism for irreversible self-deactivation of prostaglandin synthetase. J Biol Chem. 1976 Dec 10;251(23):7329–7335. [PubMed] [Google Scholar]
  11. Hamberg M., Samuelsson B. Prostaglandin endoperoxides. Novel transformations of arachidonic acid in human platelets. Proc Natl Acad Sci U S A. 1974 Sep;71(9):3400–3404. doi: 10.1073/pnas.71.9.3400. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hamberg M., Svensson J., Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A. 1975 Aug;72(8):2994–2998. doi: 10.1073/pnas.72.8.2994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hemler M. E., Lands W. E. Evidence for a peroxide-initiated free radical mechanism of prostaglandin biosynthesis. J Biol Chem. 1980 Jul 10;255(13):6253–6261. [PubMed] [Google Scholar]
  14. Lapetina E. G., Chandrabose K. A., Cuatrecasas P. Ionophore A-23187- and thrombin-induced platelet aggregation: independence from cycloxygenase products. Proc Natl Acad Sci U S A. 1978 Feb;75(2):818–822. doi: 10.1073/pnas.75.2.818. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. MacIntyre D. E., Willis A. L. Trimethoquinol is a potent prostaglandin endoperoxide antagonist [proceedings]. Br J Pharmacol. 1978 Jun;63(2):361P–361P. [PMC free article] [PubMed] [Google Scholar]
  16. Mayo J. R., Miller D. D., Feller D. R. Stereoselective inhibition of prostaglandin-induced calcium release from platelet membranes by trimetoquinol. Biochem Pharmacol. 1983 Jun 15;32(12):1952–1955. doi: 10.1016/0006-2952(83)90066-7. [DOI] [PubMed] [Google Scholar]
  17. Mayo J. R., Navran S. S., Huzoor-Akbar, Miller D. D., Feller D. R. Stereo-dependent inhibition of human platelet function by the optical isomers of trimetoquinol. Biochem Pharmacol. 1981 Aug 15;30(16):2237–2241. doi: 10.1016/0006-2952(81)90093-9. [DOI] [PubMed] [Google Scholar]
  18. Mustard J. F., Perry D. W., Ardlie N. G., Packham M. A. Preparation of suspensions of washed platelets from humans. Br J Haematol. 1972 Feb;22(2):193–204. doi: 10.1111/j.1365-2141.1972.tb08800.x. [DOI] [PubMed] [Google Scholar]
  19. Needleman P., Raz A., Ferrendelli J. A., Minkes M. Application of imidazole as a selective inhibitor thromboxane synthetase in human platelets. Proc Natl Acad Sci U S A. 1977 Apr;74(4):1716–1720. doi: 10.1073/pnas.74.4.1716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Nijkamp F. P., Moncada S., White H. L., Vane J. R. Diversion of prostaglandin endoperoxide metabolism by selective inhibition of thromboxane A2 biosynthesis in lung, spleen or platelets. Eur J Pharmacol. 1977 Jul 15;44(2):179–186. doi: 10.1016/0014-2999(77)90104-2. [DOI] [PubMed] [Google Scholar]
  21. Packham M. A., Guccione M. A., Chang P. L., Mustard J. F. Platelet aggregation and release: effects of low concentrations of thrombin or collagen. Am J Physiol. 1973 Jul;225(1):38–47. doi: 10.1152/ajplegacy.1973.225.1.38. [DOI] [PubMed] [Google Scholar]
  22. Prancan A. V., Lefort J., Chignard M., Gerozissis K., Dray F., Vargaftig B. B. L8027 and 1-nonyl-imidazole as non-selective inhibitors of thromboxane synthesis. Eur J Pharmacol. 1979 Dec 20;60(4):287–297. doi: 10.1016/0014-2999(79)90232-2. [DOI] [PubMed] [Google Scholar]
  23. REYNOLDS E. S. The use of lead citrate at high pH as an electron-opaque stain in electron microscopy. J Cell Biol. 1963 Apr;17:208–212. doi: 10.1083/jcb.17.1.208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Roth G. J., Majerus P. W. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest. 1975 Sep;56(3):624–632. doi: 10.1172/JCI108132. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Roth G. J., Stanford N., Majerus P. W. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci U S A. 1975 Aug;72(8):3073–3076. doi: 10.1073/pnas.72.8.3073. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Rotilio D., Joseph D., Hatmi M., Vargaftig B. B. Structural requirements for preventing the aspirin- and the arachidonate-induced inactivation of platelet cyclo-oxygenase: additional evidence for distinct enzymatic sites. Eur J Pharmacol. 1984 Jan 27;97(3-4):197–208. doi: 10.1016/0014-2999(84)90451-5. [DOI] [PubMed] [Google Scholar]
  27. Smith W. L., Lands W. E. Oxygenation of polyunsaturated fatty acids during prostaglandin biosynthesis by sheep vesicular gland. Biochemistry. 1972 Aug 15;11(17):3276–3285. doi: 10.1021/bi00767a024. [DOI] [PubMed] [Google Scholar]
  28. Sors H., Pradelles P., Dray F., Rigaud M., Maclouf J., Bernard P. Analytical methods for thromboxane B2 measurement and validation of radioimmunoassay by gas liquid chromatography-mass spectrometry. Prostaglandins. 1978 Aug;16(2):277–290. doi: 10.1016/0090-6980(78)90030-8. [DOI] [PubMed] [Google Scholar]
  29. Tyler H. M., Saxton C. A., Parry M. J. Administration to man of UK-37,248-01, a selective inhibitor of thromboxane synthetase. Lancet. 1981 Mar 21;1(8221):629–632. doi: 10.1016/s0140-6736(81)91551-8. [DOI] [PubMed] [Google Scholar]
  30. Vargaftig B. B. Carrageenan and thrombin trigger prostaglandin synthetase-independent aggregation of rabbit platelets: inhibition by phospholipase A2 inhibitors. J Pharm Pharmacol. 1977 Apr;29(4):222–228. doi: 10.1111/j.2042-7158.1977.tb11293.x. [DOI] [PubMed] [Google Scholar]
  31. Vargaftig B. B., Dao N. Release of vasoactive substances from guinea-pig lungs by slow-reacting substance c and arachidonic acid. Its blockade by nonsteroid anti-inflammatory agents. Pharmacology. 1971;6(2):99–108. doi: 10.1159/000136231. [DOI] [PubMed] [Google Scholar]
  32. Vargaftig B. B., Zirinis P. Platelet aggregation induced by arachidonic acid is accompanied by release of potential inflammatory mediators distinct from PGE2 and PGF2. Nat New Biol. 1973 Jul 25;244(134):114–116. doi: 10.1038/newbio244114a0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES